The PRolaCT studies — a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma

The PRolaCT studies — a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma

Abstract Background First-line treatment for prolactinomas is a medical treatment with dopamine agonists (DAs), which effectively control hyperprolactinaemia in most patients, although post-withdrawal remission rates are approximately 34%. Therefore, many patients require prolonged DA treatment, whi...

Full description

Bibliographic Details
Main Authors: Ingrid M. Zandbergen, Amir H. Zamanipoor Najafabadi, Iris C. M. Pelsma, M. Elske van den Akker-van Marle, Peter H. L. T. Bisschop, H. D. Jeroen Boogaarts, Arianne C. van Bon, Bakhtyar Burhani, Saskia le Cessie, Olaf M. Dekkers, Madeleine L. Drent, Richard A. Feelders, Johan P. de Graaf, J. Hoogmoed, Kitty K. Kapiteijn, Melanie M. van der Klauw, Willy-Anne C. M. Nieuwlaat, Alberto M. Pereira, Aline M. E. Stades, Annenienke C. van de Ven, Iris M. M. J. Wakelkamp, Wouter R. van Furth, Nienke R. Biermasz, on behalf of the Dutch Prolactinoma Study Group
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Trials
Subjects:
Prolactinoma
Pituitary tumour
Dopamine agonist
Endoscopic transsphenoidal resection
Randomised clinical trial
Observational cohort
Online Access:https://doi.org/10.1186/s13063-021-05604-y

Internet

https://doi.org/10.1186/s13063-021-05604-y

Similar Items